Capstan Therapeutics
@capstantx
Followers
186
Following
1
Media
13
Statuses
17
Multiplying the therapeutic possibilities for patients by developing targeted in vivo RNA technologies.
San Diego, CA
Joined January 2022
Our Director of Antibody CMC, Qian-Chen Yong, Ph.D., will speak at @chi_peptalk next week on the potential of targeted lipid nanoparticles #tLNPs as a new and exciting treatment modality at the forefront of in vivo CAR-T. #CHIPepTalk #CellSeeker
0
0
0
Happy Holidays from all of us at #TeamCapstan! We are grateful for all those who support our mission to develop innovative treatments for patients. Here's to a joyful holiday season and an even brighter year ahead!
0
0
1
Capstan's new website honors the groundbreaking advancements in mRNA and CAR T therapy that have made in vivo CAR T possible, and showcases our vision to be the leader in in vivo CAR T therapy as we prepare for a transformative 2025. Learn more:
0
0
1
This week Capstan President & CEO @lshawverO was featured as one of the 500 Most Influential People in San Diego by @SDbusiness. We’re proud to have such a dedicated and passionate leader at the helm of Team Capstan!. Read more here:
0
0
0
This weekend we announced positive preclinical data on our lead in vivo CAR-T candidate, CPTX2309, at the @ACRheum Convergence 2024. Capstan plans to advance CPTX2309 into the clinic mid-2025. Read more here: #CellSeeker #ImmuneReset
0
0
1
Capstan will participate in upcoming investor conferences hosted by @Stifel and @Piper_Sandler. Read more in today’s press release: . #PSCHealthcare2024
0
0
2
Last week our Co-Founder and VP of Research Haig Aghajanian, Ph.D., gave a standout presentation on the benefits of in vivo CAR T using targeted LNPs, the backbone of our scientific approach, at #ASGCT24. Sally Church (@MaverickNY) remarks on his talk at the link below.
Seek to be inspired – this week's weekend reading is 10 short, yet important lessons on in vivo CAR-T cell therapy:.
0
0
2
We are honored to be recognized among this year’s @endpts 11! Thank you to all our Capstaneers that contribute to our mission to multiply the therapeutic possibilities for patients. #Endpoints11
0
2
4
Next month Capstan will participate in investor conferences hosted by @GoldmanSachs and Leerink Partners. More in today’s press release:
0
0
2
Our CSO Adrian Bot spoke with @AsherMullard of @NatRevDrugDisc about how Capstan is innovating in the field of in vivo CAR T, advancing a solution that is scalable, tunable, and potentially safer for patients suffering from autoimmune disease.
In vivo CAR T cells move into clinical trials Find out how drug developers are aiming to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity in this news article published today
0
2
3
Next month Capstan management will attend the @MorganStanley 22nd Annual Global Healthcare Conference. More in today’s release:
0
0
0
Capstan Co-Founder @carlhjune speaks on the benefits of in vivo CAR T in this @Forbes piece, including its vast therapeutic potential and its potential safety, efficiency, and cost benefits. Read more here:
0
1
4
Our CMO @rfsquared spoke with @PharmaVoice about the potential to retain the benefits of CAR-T & eliminate the drawbacks of autologous/allogeneic approaches by using in vivo CAR-T therapies, including our tLNP delivery method. More: #autoimmunedisorders.
0
1
5
Our lead development candidate, CPTX2309, is an in vivo CAR-T for autoimmune disorders. We’re excited to continue advancing this program and believe it has the potential to meet the unique needs of patients with B cell-mediated autoimmune diseases.
0
1
4
Multiplying the CAR T therapeutic possibilities means taking this modality in vivo. We’re proud to be leaders in the emerging in vivo CAR T field, with our targeted LNP platform technology building on the benefits of prior in vivo approaches without their limitations.
0
5
10